PT  - JOURNAL ARTICLE
AU  - KUNISAKI, CHIKARA
AU  - IMADA, TOSHIO
AU  - YAMADA, ROPPEI
AU  - HATORI, SHINSUKE
AU  - ONO, HIDETAKA
AU  - OTSUKA, YUICHI
AU  - MATSUDA, GORO
AU  - NOMURA, MASATO
AU  - AKIYAMA, HIROTOSHI
AU  - KUBO, AKIRA
AU  - SHIMADA, HIROSHI
TI  - Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma
DP  - 2005 Jul 01
TA  - Anticancer Research
PG  - 2973--2977
VI  - 25
IP  - 4
4099  - http://ar.iiarjournals.org/content/25/4/2973.short
4100  - http://ar.iiarjournals.org/content/25/4/2973.full
SO  - Anticancer Res2005 Jul 01; 25
AB  - Background: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. Patients and Methods: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. Results: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. Conclusion: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved